HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: Supplement Labeling Guide Corrected, Nu Skin Settles

This article was originally published in The Tan Sheet

Executive Summary

Trifecta of APIs in Texas firm's products; 5-hour Energy wins trademark case; New Global Energy share repurchase; and more news in brief.

You may also be interested in...



OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.

OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.

Supplement, Drug Co-Packaging Potential Could Be Clipped In FDA Proposed Rule

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN encourages FDA to allow. FDA will determine on a case-by-case basis whether co-packaged OTCs and supplements already available are in violation of a proposed rule on drug co-packaging.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel